What is the official website of Sandoz México ?

The official website of Sandoz México is https://sandoz.com.mx.

What is Sandoz México's cybersecurity risk score?

Sandoz México has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Sandoz México experienced?

According to Rankiteo, Sandoz México currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Sandoz México been affected by any supply chain cyber incidents ?

According to Rankiteo, Sandoz México has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Sandoz México have SOC 2 Type 1 certification ?

According to Rankiteo, Sandoz México is not certified under SOC 2 Type 1.

Does Sandoz México have SOC 2 Type 2 certification ?

According to Rankiteo, Sandoz México does not hold a SOC 2 Type 2 certification.

Does Sandoz México comply with GDPR ?

According to Rankiteo, Sandoz México is not listed as GDPR compliant.

Does Sandoz México have PCI DSS certification ?

According to Rankiteo, Sandoz México does not currently maintain PCI DSS compliance.

Does Sandoz México comply with HIPAA ?

According to Rankiteo, Sandoz México is not compliant with HIPAA regulations.

Does Sandoz México have ISO 27001 certification ?

According to Rankiteo,Sandoz México is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Sandoz México operate in ?

Sandoz México operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Sandoz México have ?

Sandoz México employs approximately 170 people worldwide.

Does Sandoz México own any subsidiaries ?

Sandoz México presently has no subsidiaries across any sectors.

How many LinkedIn followers does Sandoz México have ?

Sandoz México's official LinkedIn profile has approximately 21,173 followers.

What is the NAICS classification code for Sandoz México ?

Sandoz México is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Sandoz México have a Crunchbase profile ?

No, Sandoz México does not have a profile on Crunchbase.

Does Sandoz México have a LinkedIn profile ?

Yes, Sandoz México maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/sandozmexico.

How many cybersecurity incidents has Sandoz México experienced ?

As of September 17, 2026, Rankiteo reports that Sandoz México has not experienced any cybersecurity incidents.

How many peer or competitor companies does Sandoz México have ?

Sandoz México has an estimated 5,766 peer or competitor companies worldwide.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Sandoz México

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

Sandoz México Vendor Cyber Rating & Cyber Score

sandoz.com.mx

Add Your Compliance Badge

Somos líder mundial en medicamentos genéricos y biocomparables. Estamos presentes en más de 100 países y nuestros medicamentos atienden a unos 500 millones de personas cada año. Consulta nuestro aviso de privacidad en: https://www.sandoz.com.mx/aviso-de-privacidad.html

Sandoz México

Sandoz México CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Sandoz México Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Sandoz México

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Sandoz México in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Sandoz México in 2026.

Incident Types Sandoz México vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Sandoz México in 2026.

Incident History - Sandoz México (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Sandoz México Subsidiaries

Sandoz México

Pharmaceutical Manufacturing

Website: https://sandoz.com.mx

Company Size: 5,001-10,000 employees

SandozPharmaceutical Manufacturing

Sandoz do BrasilFabricação de produtos farmoquímicos e farmacêuticos

Lek PharmaceuticalsPharmaceutical Manufacturing

Sandoz ItaliaPharmaceutical Manufacturing

Sandoz CanadaPharmaceutical Manufacturing

Sandoz Czech RepublicPharmaceutical Manufacturing

Sandoz EgyptPharmaceutical Manufacturing

Sandoz FrancePharmaceutical Manufacturing

Sandoz UK & IrelandPharmaceutical Manufacturing

Sandoz NederlandPharmaceutical Manufacturing

Sandoz IberiaPharmaceutical Manufacturing

Sandoz SrbijaPharmaceutical Manufacturing

Sandoz Australia & New ZealandPharmaceutical Manufacturing

Sandoz SverigePharmaceutical Manufacturing

Life at SandozArzneimittelherstellung

Sandoz PolskaPharmaceutical Manufacturing

Sandoz DanmarkPharmaceutical Manufacturing

Sandoz HungáriaPharmaceutical Manufacturing

Sandoz HrvatskaPharmaceutical Manufacturing

Sandoz India Pvt LtdPharmaceutical Manufacturing

Sandoz RomaniaPharmaceutical Manufacturing

Sandoz ÖsterreichPharmaceutical Manufacturing

Sandoz BelgiumPharmaceutical Manufacturing

Sandoz in DeutschlandPharmaceutical Manufacturing

Loading…

Sandoz México Similar Companies

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Loading…

NEWS

Sandoz México CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

July 21, 2021 07:00 AM

Generics, Biosimilar Leader to Expand Access, Reduce Costs

Q: How did Sandoz achieve its leading position in the generics sector and what strategies has the company implemented to maintain its...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-65388

SUMMARY

A remote attacker who controls a container registry may be able to direct a client's token request to a host of the attacker's choice, and disclose the victim's registry credentials to that host. This vulnerability is addressed in containerization version 0.41.0.

Published

Date2026-09-16

Updated

Date2026-09-16

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

https://github.com/apple/containerization/security/advisories/GHSA-mx96-5vvg-x2mg

CVE-2026-61599

SUMMARY

djust provides Phoenix LiveView-style reactive server-side rendering for Django with Rust-powered performance. Prior to version 1.0.7, the djust live transport resolves the LiveView to mount from a client-supplied dotted path by calling `__import__(module_path, ...)`. The module is imported — running its top-level code (import side effects) — before the framework checks that the resolved object is a `LiveView` subclass and before any per-view authentication. The `LIVEVIEW_ALLOWED_MODULES` allowlist that should contain this is fail-open (`if allowed_modules:` — skipped when the setting is unset, the framework default) and uses loose `startswith` matching. An unauthenticated WebSocket client (the WS handshake does not require auth; per-view auth runs only after import + instantiate) can therefore send a `mount` / `live_redirect_mount` / `url_change` frame (or an SSE mount) with `view = "<any.importable.module>.AnyName"` and cause the server to import — and execute the top-level code of — any importable Python module by name. Version 1.0.7 fixes the issue with a fail-closed resolution gate (`djust._view_resolution.is_view_import_allowed`): a client view path resolves only if (a) its module is already loaded (`sys.modules` — so resolving runs no new code; URL-routed views loaded by URLconf at startup keep working with zero config) or (b) it matches `LIVEVIEW_ALLOWED_MODULES` on a module-segment boundary (explicit opt-in for lazily-imported views). The gate runs before `__import__` at all three sinks (+ defense-in-depth inside `_instantiate_view`). As a workaround, set `LIVEVIEW_ALLOWED_MODULES` to the narrow list of modules that contain your mountable LiveView classes. (Note: pre-patch the allowlist is `startswith`-matched and the import still precedes the subclass check, so this is mitigation, not a complete fix.)

Published

Date2026-09-16

Updated

Date2026-09-16

RISK INFORMATION (Score: )

cvss4

Base Score: 8.8

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:H/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-61596

SUMMARY

djust provides Phoenix LiveView-style reactive server-side rendering for Django with Rust-powered performance. Prior to version 1.0.7, djust's per-object authorization (`get_object` + `has_object_permission`, ADR-017) was enforced on the WebSocket mount and event paths but not on three other render entry points: (a) the initial HTTP GET render, (b) SPA `url_change` navigation, and (c) `{% live_render %}` embedded child views. An authenticated user could therefore view (and on some paths act on) an object they are not authorized for by loading the page directly, navigating to it via SPA url-change, or composing it as an embedded child — a classic IDOR / broken object-level access control on object-scoped views. This is fixed in djust 1.0.7. All render entry points now route through a shared `enforce_object_permission` chokepoint: HTTP GET returns 403, `url_change` emits a `permission_denied` frame and skips the render, and `{% live_render %}` (eager + lazy) refuses the embed. Views without a custom `get_object` are unaffected (no-op). No reliable workaround short of upgrading. Do not expose object-scoped views through the HTTP-GET / url_change / live_render paths until patched.

Published

Date2026-09-16

Updated

Date2026-09-16

RISK INFORMATION (Score: 7.1)

cvss3

Base Score: 7.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:L/A:N

Impact Score

4.2

Exploitability

2.8

REFERENCES

CVE-2026-61589

SUMMARY

djust provides Phoenix LiveView-style reactive server-side rendering for Django with Rust-powered performance. Prior to version 1.0.7, the WebSocket `handle_mount` and `ViewRuntime._build_request` rebuild an `HttpRequest` via `RequestFactory().get(...)` with no `HTTP_HOST`, so `request.get_host()` defaulted to `"testserver"` on the live path. Host/subdomain/domain `TenantResolver`s then misresolved the tenant — `None` on the live path while the HTTP path resolved correctly. With `STRICT_MODE=False` the tenant-scoped managers returned unscoped rows (cross-tenant disclosure); with the default they returned an empty queryset (broken tenancy). This is fixed in djust 1.0.7. The handshake Host is extracted from the ASGI scope, validated against `ALLOWED_HOSTS` (the same logic as the CSWSH Origin gate, parsed with Django's `split_domain_port` so malformed Hosts are rejected at the boundary), and propagated — with the TLS scheme — into the reconstructed request, so live-path tenant resolution matches HTTP exactly. There is no known workaround on the live path short of upgrading. Users are most exposed when combined with `STRICT_MODE=False`.

Published

Date2026-09-16

Updated

Date2026-09-16

RISK INFORMATION (Score: 6.3)

cvss3

Base Score: 6.3

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:C/C:H/I:N/A:N

Impact Score

Exploitability

1.8

REFERENCES

CVE-2026-61588

SUMMARY

djust provides Phoenix LiveView-style reactive server-side rendering for Django with Rust-powered performance. Prior to version 1.0.7, when a Django `Model` instance is assigned to a public view attribute, djust serialized it to the client with no sensitive-field denylist — sending fields such as `password` (the hash), privilege flags (e.g. `is_staff` / `is_superuser`), tokens, and other PII to the browser. Because exposing model objects to templates is a normal djust pattern, this could leak credentials/PII without the developer realizing the full object crossed the wire. This is fixed in djust 1.0.7. Model serialization applies a secure-by-default sensitive-field denylist (password/hash/token/secret-style fields and known privilege flags are withheld) with an identity-subset fallback. As a workaround, keep `Model` instances on `_private` attributes and expose only the specific fields needed, until patched.

Published

Date2026-09-16

Updated

Date2026-09-16

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

2.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Sandoz México Vendor Cyber Rating & Cyber Score

Sandoz México A.I CyberSecurity Scoring

Sandoz México CyberSecurity News & History

Sandoz México Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Sandoz México

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Sandoz México vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Sandoz México (X = Date, Y = Severity)

Sandoz México Subsidiaries

Sandoz México

Sandoz México Similar Companies

Grifols

Intas Pharmaceuticals

Novo Nordisk

AbbVie

Teva Pharmaceuticals

Hikma Pharmaceuticals

Eli Lilly and Company

Lonza

Johnson & Johnson Innovative Medicine

Sandoz México CyberSecurity News

Generics, Biosimilar Leader to Expand Access, Reduce Costs

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Sandoz México CyberSecurity News & History

Sandoz México Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Sandoz México

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Sandoz México vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Sandoz México (X = Date, Y = Severity)

Sandoz México Subsidiaries

Sandoz México

Sandoz México Similar Companies

Grifols

Intas Pharmaceuticals

Novo Nordisk

AbbVie

Teva Pharmaceuticals

Hikma Pharmaceuticals

Eli Lilly and Company

Lonza

Johnson & Johnson Innovative Medicine

Sandoz México CyberSecurity News

Generics, Biosimilar Leader to Expand Access, Reduce Costs

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo